Bruce & Co’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,556,247
| Closed | -$3.44M | – | 39 |
|
|
2023
Q2 | $3.44M | Hold |
1,556,247
| – | – | 0.96% | 19 |
|
|
2023
Q1 | $3.95M | Sell |
1,556,247
-1,065
| -0.1% | -$2.1K | 1.08% | 19 |
|
|
2022
Q4 | $2.91M | Hold |
1,557,312
| – | – | 0.75% | 23 |
|
|
2022
Q3 | $4M | Hold |
1,557,312
| – | – | 1.1% | 19 |
|
|
2022
Q2 | $3M | Hold |
1,557,312
| – | – | 0.71% | 22 |
|
|
2022
Q1 | $4.63M | Buy |
1,557,312
+114,000
| +8% | +$429K | 0.95% | 20 |
|
|
2021
Q4 | $6.48M | Buy |
1,443,312
+100,000
| +7% | +$474K | 1.3% | 17 |
|
|
2021
Q3 | $6.53M | Buy |
1,343,312
+180,000
| +15% | +$992K | 1.39% | 17 |
|
|
2021
Q2 | $7.93M | Hold |
1,163,312
| – | – | 1.52% | 17 |
|
|
2021
Q1 | $8.21M | Buy |
1,163,312
+234,000
| +25% | +$1.69M | 1.54% | 19 |
|
|
2020
Q4 | $5.82M | Buy |
929,312
+50,000
| +6% | +$294K | 1.12% | 22 |
|
|
2020
Q3 | $4.76M | Buy |
879,312
+312,760
| +55% | +$1.55M | 0.99% | 21 |
|
|
2020
Q2 | $2.96M | Buy |
566,552
+100,000
| +21% | +$444K | 0.64% | 25 |
|
|
2020
Q1 | $1.47M | Buy |
466,552
+200,000
| +75% | +$738K | 0.34% | 31 |
|
|
2019
Q4 | $1.07M | Hold |
266,552
| – | – | 0.21% | 35 |
|
|
2019
Q3 | $1.15M | Hold |
266,552
| – | – | 0.24% | 36 |
|
|
2019
Q2 | $1.06M | Buy |
+266,552
| New | +$1.27M | 0.23% | 35 |
|
Bruce & Co's PRTK Position: Q3 2023 in Review
Bruce & Co sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 1,556,247 shares — an estimated $3.44M sold.
Bruce & Co first reported a position in PRTK in Q2 2019 and held it in 17 quarters. The position peaked at $8.21M in Q1 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Bruce & Co reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Bruce & Co sold 1,556,247 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $3.44M.
- Bruce & Co first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2019 and held it in 17 quarters.
- Bruce & Co's Paratek Pharmaceuticals, Inc. position peaked at $8.21M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Bruce & Co's 13F filing for Q3 2023, filed 13 Nov 2023.